Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of inhaled ARIKAYCE added to azithromycin and ethambutol in newly diagnosed non-cavitary MAC lung disease
MOH_2020-12-07_009546Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Oct 2020
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mycobacterium avium-intracellulare infection (MAI) and nontuberculous mycobacterial lung disease comparing ARIKAYCE + azithromycin + ethambutol with Placebo + azithromycin + ethambutol (2 arms). Planned start Oct 2020; status: not yet recruiting.
02
Drugs
amikacin liposome
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on MOH_2020-12-07_009546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-07_009546.